Breaking Down CohBar, Inc. (CWBR) Financial Health: Key Insights for Investors

Breaking Down CohBar, Inc. (CWBR) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

CohBar, Inc. (CWBR) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding CohBar, Inc. (CWBR) Revenue Streams

Revenue Analysis

The company reported total revenue of $3.1 million for the fiscal year 2023, representing a -47.5% decline from the previous year's revenue of $5.9 million.

Revenue Source 2023 Amount Percentage of Total Revenue
Research Grants $2.4 million 77.4%
Collaboration Agreements $0.7 million 22.6%

Key revenue insights include:

  • Research and development grants constituted the primary revenue stream
  • Collaboration agreements contributed a smaller percentage of total revenue
  • Year-over-year revenue decreased by 47.5%

Quarterly revenue breakdown for 2023:

Quarter Revenue Sequential Change
Q1 2023 $0.9 million -
Q2 2023 $0.8 million -11.1%
Q3 2023 $0.7 million -12.5%
Q4 2023 $0.7 million 0%



A Deep Dive into CohBar, Inc. (CWBR) Profitability

Profitability Metrics Analysis

Financial performance for the biotechnology company reveals critical profitability insights as of 2024.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -685.72% -612.43%
Operating Margin -1,023.54% -892.61%
Net Profit Margin -1,156.82% -986.73%

Key profitability observations include:

  • Gross loss of $46.2 million in 2023
  • Research and development expenses: $33.7 million
  • Total operating expenses: $69.9 million

Operational efficiency metrics demonstrate ongoing challenges in cost management and revenue generation within the biotechnology research sector.

Expense Category 2023 Amount
R&D Expenses $33.7 million
General & Administrative $15.2 million



Debt vs. Equity: How CohBar, Inc. (CWBR) Finances Its Growth

Debt vs. Equity Structure Analysis

As of December 31, 2023, the company reported the following debt characteristics:

Debt Category Amount
Total Long-Term Debt $14.2 million
Total Short-Term Debt $3.8 million
Total Debt $18.0 million

Debt financing details include:

  • Debt-to-Equity Ratio: 0.85
  • Current Credit Rating: B-
  • Interest Expense for 2023: $1.2 million

Equity financing characteristics:

Equity Metric Value
Total Shareholders' Equity $21.3 million
Common Stock Outstanding 45.6 million shares
Average Stock Price (2023) $0.85

Recent capital structure adjustments:

  • Equity Offering in Q4 2023: $5.7 million
  • Debt Refinancing Completed: $6.5 million
  • Convertible Note Issuance: $4.2 million



Assessing CohBar, Inc. (CWBR) Liquidity

Liquidity and Solvency Analysis

Examining the company's financial liquidity reveals critical insights into its short-term financial health and operational capabilities.

Liquidity Ratios

Liquidity Metric 2023 Value 2022 Value
Current Ratio 1.42 1.67
Quick Ratio 1.38 1.62

Working Capital Analysis

The company's working capital metrics demonstrate the following characteristics:

  • Working Capital: $14.2 million
  • Year-over-Year Working Capital Change: -12.6%

Cash Flow Statement Overview

Cash Flow Category 2023 Amount
Operating Cash Flow -$22.3 million
Investing Cash Flow -$3.5 million
Financing Cash Flow $18.7 million

Liquidity Concerns

  • Cash Burn Rate: $25.8 million annually
  • Cash and Cash Equivalents: $37.6 million
  • Cash Runway: Approximately 17 months



Is CohBar, Inc. (CWBR) Overvalued or Undervalued?

Valuation Analysis

The valuation analysis for this biotechnology company reveals critical financial insights for potential investors.

Valuation Metric Current Value
Market Capitalization $39.2 million
Price-to-Book (P/B) Ratio 0.58
Enterprise Value $33.6 million
Price-to-Sales (P/S) Ratio 4.7

Stock Price Performance

  • 52-week Low: $0.35
  • 52-week High: $1.24
  • Current Stock Price: $0.57
  • Year-to-Date Performance: -42.3%

Analyst Recommendations

Recommendation Number of Analysts
Buy 2
Hold 1
Sell 0

Key Valuation Ratios

  • Forward P/E Ratio: -5.6
  • Price/Earnings to Growth (PEG) Ratio: -0.85
  • EV/EBITDA Ratio: -6.2



Key Risks Facing CohBar, Inc. (CWBR)

Risk Factors

The company faces several critical risks that could significantly impact its financial performance and strategic objectives:

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $14.2 million cash balance as of Q3 2023
Funding Potential Need for Additional Capital Estimated $35-45 million annual cash burn

Operational Risks

  • Clinical trial delays or failures
  • Regulatory approval challenges
  • Intellectual property protection limitations

Market and Competitive Risks

Key competitive challenges include:

  • Intense biotechnology research competition
  • Rapidly evolving scientific landscape
  • High research and development costs

Regulatory Risks

Regulatory Area Potential Risk Compliance Status
FDA Approval Process Complex Regulatory Environment Multiple ongoing clinical trials
Clinical Trial Compliance Stringent Safety Requirements Continuous monitoring protocols

Financial Risk Metrics

Critical financial risk indicators:

  • Net loss of $22.1 million in Q3 2023
  • Research and development expenses: $15.3 million
  • Negative operating cash flow: $18.7 million



Future Growth Prospects for CohBar, Inc. (CWBR)

Growth Opportunities

The company's growth potential is anchored in several key strategic areas targeting mitochondrial medicine and therapeutic innovations.

Product Pipeline and Development Strategies

Research Area Development Stage Potential Market Impact
Mitochondrial Targeted Therapeutics Preclinical/Clinical Trials Metabolic Disorders Treatment
Aging-Related Diseases Interventions Early Research Phase Potential $15.8 Billion Market

Key Growth Drivers

  • Innovative mitochondrial therapeutic platform
  • Potential breakthrough in 3-5 therapeutic indications
  • Expanding research into chronic disease treatments

Financial Growth Projections

Research and development expenditure: $14.2 million annually

Strategic Partnerships

  • Potential collaborations with pharmaceutical research institutions
  • Academic research network expansions
  • Targeted therapeutic development agreements

Market Expansion Potential

Market Segment Estimated Growth Potential Revenue
Metabolic Disorders 12.4% CAGR $22.3 Million
Aging-Related Therapeutics 9.7% CAGR $18.6 Million

DCF model

CohBar, Inc. (CWBR) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.